Palisade Bio (NASDAQ:PALI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday, Zacks.com reports. The firm presently has a $0.50 target price on the stock. Zacks Investment Research‘s price target points to a potential downside of 6.92% from the company’s previous […]
Palisade Bio (NASDAQ:PALI – Get Rating) is one of 259 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Palisade Bio to related companies based on the strength of its analyst recommendations, institutional ownership, earnings, dividends, valuation, risk and profitability. Institutional & Insider Ownership […]
Palisade Bio, Inc. (NASDAQ:PALI – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 481,800 shares, a decline of 59.5% from the April 30th total of 1,190,000 shares. Based on an average daily trading volume, of 1,560,000 shares, […]